Boston Scientific Corporation
BSX
$101.49
$2.572.59%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 20.68% | 44.31% | -34.21% | -2.18% | 0.20% |
| Total Depreciation and Amortization | 13.73% | -1.61% | 2.30% | -2.88% | 4.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 257.38% | -84.20% | 254.13% | -44.39% | 180.00% |
| Change in Net Operating Assets | 95.18% | 179.43% | 71.87% | -1,203.51% | 67.61% |
| Cash from Operations | 45.31% | 23.25% | 395.73% | -82.86% | 37.11% |
| Capital Expenditure | -54.75% | -15.48% | 13.41% | 32.96% | -40.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -100.00% |
| Cash Acquisitions | -203.28% | -2,247.92% | -2.13% | 94.07% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 90.91% | -77.94% | -13.33% | -957.14% | 187.50% |
| Cash from Investing | -159.57% | -426.57% | 4.91% | 72.93% | -434.52% |
| Total Debt Issued | 759.09% | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | 100.00% |
| Issuance of Common Stock | -70.83% | 269.23% | -67.50% | 370.59% | -77.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 175.68% | -5,450.00% | 98.43% | -335.19% | 400.00% |
| Cash from Financing | 2,957.14% | -70.83% | -98.47% | 10,360.00% | -6.25% |
| Foreign Exchange rate Adjustments | -250.00% | 700.00% | 85.71% | -275.00% | 180.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -396.12% | -172.92% | -60.79% | 1,971.43% | -115.01% |